When Cabaletta Bio and Phathom Pharmaceuticals penciled in $100 million IPOs alongside 4D Molecular Therapeutics back in the beginning of October, they appeared to be riding on a wave of positive sentiments in the public markets — albeit against some chatter in the background about how long the buoyant conditions will last.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,